Navigation Links
BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
Date:7/28/2009

BIRMINGHAM, Ala., July 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its second quarter 2009 financial results will be released on Thursday, July 30, 2009. BioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results and provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Stuart Grant, Chief Financial Officer and Dr. William P. Sheridan, Chief Medical Officer.

The Web cast can be accessed by logging onto http://www.biocryst.com. Please connect to the Web site at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed. To participate in the conference call, please dial 1-877-627-6566 (United States) or 1-719-325-4922 (International). No passcode is needed for the call. The audio portion of the Web cast will be archived and available for replay for at least 14 days.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in oncology, infectious and autoimmune diseases. BioCryst has two product candidates in pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to expand its portfolio of next-generation therapeutic candidates with the potential to address the unmet medical needs of patients and physicians. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings, Ltd. validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at www.shareholder.com/biocryst/edgar.cfm.

BCRXW


'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
2. BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
3. BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition
4. BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
5. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
6. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
7. BioCryst to Present at the JMP Healthcare Focus Conference
8. BioCryst to Present at UBS 2008 Global Life Sciences Conference
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
11. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising treatments in ... the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient ... this year following FDA approval of a second application for a single patient, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board ... BIO 2016 in San Francisco. Located at booth number 7301, representatives from the ... questions and discuss the Thai biotechnology and life sciences sector. , Deputy ...
(Date:5/25/2016)... ... ... at the University of Athens say they have evidence that the variety of different ... lead to one good one. Surviving Mesothelioma has just posted an article on the ... 98 mesothelioma patients who got a second kind of drug therapy after ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... attacks, diabetes, and traumatic injuries, will be accelerated by research at Worcester Polytechnic ... into engines of wound healing and tissue regeneration. , The novel method, developed ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):